Sage Therapeutics to Present Data at the Society of Biological Psychiatry 71st Annual Scientific Meeting
March 28, 2016 07:00 ET
|
SAGE Therapeutics
First time detailed data for SAGE-547 in postpartum depression (PPD) to be presented PPD data includes secondary endpoints and timeline of response SAGE-718 pre-clinical data unveiled in...
Sage Therapeutics to Present SAGE-547 Clinical Data and SRSE Health Economic Data in Five Abstracts at the American Academy of Neurology 2016 Annual Meeting
March 03, 2016 16:32 ET
|
SAGE Therapeutics
An In-Depth Look at the Phase 1/2 SRSE Trial Data and Patient Characteristics Health Economic Burden of Treatment Defined for SRSE Data on Exploratory Results in Essential Tremor CAMBRIDGE, Mass.,...
Sage Therapeutics to Present at the Cowen & Co. 36th Annual Health Care Conference
February 29, 2016 16:10 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous...
Sage Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results
February 24, 2016 07:00 ET
|
SAGE Therapeutics
Top-line Results of Phase 3 STATUS Trial for SAGE-547 in SRSE Expected in 2H 2016 Robust, Wholly-Owned Pipeline Includes 6 Novel Compounds in Evaluation across Multiple CNS Indications 3 Clinical...
Sage Therapeutics to Report Fourth Quarter and Full Year 2015 Financial Results on Wednesday, February 24, 2016
February 17, 2016 16:05 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Feb. 17, 2016 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous...
Sage Therapeutics to Present at the 2016 Leerink Global Healthcare Conference
February 03, 2016 07:00 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Feb. 03, 2016 (GLOBE NEWSWIRE) -- SAGE Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous...
Sage Therapeutics Announces Pricing of Public Offering of Common Stock
January 06, 2016 21:36 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Sage Therapeutics, Inc. (Nasdaq:SAGE), a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives...
Sage Therapeutics Announces Proposed Public Offering of Common Stock
January 05, 2016 16:08 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Sage Therapeutics, Inc. (Nasdaq:SAGE), a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the...
Sage Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference
January 04, 2016 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Jan. 04, 2016 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous...
SAGE Updates Guidance for Top-Line Results of Phase 3 STATUS Trial of SAGE-547
December 15, 2015 06:30 ET
|
SAGE Therapeutics
CAMBRIDGE, Mass., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Sage Therapeutics (NASDAQ:SAGE) today announced updated guidance for the expected readout of top-line results for its STATUS Trial (SAGE-547...